AstraZeneca reported Thursday that its asthma treatment Tezspire, co‑developed with Amgen, achieved both its primary and secondary endpoints in a late‑stage clinical trial for eosinophilic esophagitis (EoE). The trial demonstrated that patients receiving Tezspire experienced a statistically significant reduction in esophageal inflammation compared with those given a placebo, and also reported fewer difficulties with swallowing.
Trial design and results
The randomized, double‑blind study enrolled adults diagnosed with eosinophilic esophagitis, a chronic inflammatory disorder of the esophagus that can cause pain, food impaction, and long‑term tissue damage. Participants received either Tezspire or a matching placebo over a predefined treatment period. The primary endpoint measured the proportion of patients achieving histologic remission—defined as a marked decrease in eosinophil counts within the esophageal tissue. The secondary endpoint evaluated patient‑reported outcomes related to dysphagia, or difficulty swallowing.
According to the data released, a significantly higher percentage of the Tezspire group met the histologic remission criteria than the placebo group. Moreover, patients on Tezspire reported meaningful improvements in swallowing frequency and ease, indicating both an objective and a quality‑of‑life benefit.
How Tezspire works
Tezspire belongs to a class of targeted therapies known as monoclonal antibodies. It blocks the activity of thymic stromal lymphopoietin (TSLP), a protein that can trigger inflammatory pathways linked to eosinophilic conditions as well as severe asthma. By inhibiting TSLP, Tezspire reduces the cascade of immune responses that lead to tissue inflammation.
Regulatory status and future outlook
Tezspire is already approved in the United States, the European Union, and several other markets as an add‑on treatment for severe asthma. The positive EoE trial results could pave the way for expanded labeling, allowing physicians to prescribe the drug for patients suffering from this debilitating esophageal disease. AstraZeneca indicated that it will engage with regulatory agencies worldwide to discuss the new data and potential label extensions.
Industry analysts view the trial’s success as a significant milestone for both AstraZeneca and Amgen, highlighting the growing importance of biologic therapies that target specific immune pathways. If approved for eosinophilic esophagitis, Tezspire would join a limited roster of treatments for the condition, offering patients an alternative to dietary management and steroid‑based therapies.
Implications for patients and providers
For individuals living with eosinophilic esophagitis, the availability of an effective, injectable biologic could reduce reliance on restrictive diets and long‑term steroid use, both of which carry their own risks. Gastroenterologists and allergists will likely monitor the regulatory process closely, as the drug’s safety profile in asthma patients has already been well documented.
While the trial focused on adult participants, AstraZeneca hinted that pediatric studies may be planned, reflecting the company’s broader commitment to addressing eosinophilic diseases across age groups.
Overall, the announcement underscores the continued advancement of precision medicine in treating inflammatory disorders, aligning with the pharmaceutical industry’s shift toward targeted, mechanism‑based therapies.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
